ÂÜÀòÂÒÂ×

Dr. Wantanee Phuapradit joined the preclinical R&D US team of Inflarx in 2022 as a senior director, leading the drug product development and all CMC related activities of small drug molecules. She holds a Ph.D. in Pharmaceutics with over 30 years of extensive experience in pharmaceutical oral dosage development, scale-up, technology transfer of generics, 505b2 and new chemical entities. Her accolades include over 25 patents of the drug delivery systems, 10 scientific publications, and over 20 presentations/speaker events all specializing in pharmaceutical excellence.

Prior joining Inflarx, Dr. Phuapradit has been serving as a scientific advisor and subject-matter expert of drug product development along with multiple R&D leadership roles and responsibilities in various pharmaceutical R&D organizations. She has been involved all phases of drug development including early-stage product selection, product development, technology transfer, regulatory submission, FDA approval and commercialization.